

2022 Information

Date of announcement	Date of announcement	Statement
2022/01/21	13:36:35	<p>Announcement of the high liquidity assets, short-term debt, short-term notes payable and long-term liabilities due within 1 year.</p> <p>1.Date of occurrence of the event:2022/01/20</p> <p>2.Cause of occurrence: According to the letter No. 1091806531 of TWSE</p> <p>3.Financial information date: December 2021</p> <p>4.Cash and cash equivalents(Unit:NT'000):302866</p> <p>5.Financial assets at fair value through profit or loss–current (Unit:NT'000):360401</p> <p>6.Financial assets at fair value through other comprehensive income–current (Unit:NT'000):0</p> <p>7.Non-current assets that are TWSE or GTSM listed securities (including unrealized valuation amount) (Unit:NT'000):0</p> <p>8.Short-term debt (Unit:NT'000):0</p> <p>9.Short-term notes payable (Unit:NT'000):0</p> <p>10.Long-term liabilities due within 1 year (Unit:NT'000):0</p> <p>11.Other accounting accounts (Unit:NT'000):0</p> <p>12.Countermeasures: None.</p> <p>13.Any other matters that need to be specified: None.</p>
2022/01/26	16:53:36	<p>To announce that the Company signed a medium-term loan agreement with the bank.</p> <p>1.Date of occurrence of the event:2022/01/26</p> <p>2.Counterparty to the contract or commitment: Mega International Commercial Bank Co., Ltd Taohsin Branch</p> <p>3.Relationship with the Company: none</p> <p>4.Starting and ending dates (or rescission date) of the contract or commitment: Five years right after first drawdown</p> <p>5.Major content (not applicable where rescinded): NT\$1 billion medium-term loan</p> <p>6.Restrictive covenants (not applicable where rescinded): The borrowing must comply with the relevant regulations of the "Accelerated Investment Project Loan for Enterprises Investing in Taiwan".</p> <p>7.Commitment (not applicable where rescinded):none</p> <p>8.Any other important agreement (not applicable where rescinded): With the land No. 560 in the Luzhu District, Taoyuan City and its buildings, No. 207-1, 207-2, 207-3, 207-4 and 207-5, as collaterals, the amount of pledge set at NTD1,032,700,000.</p> <p>9.Effect on company finances and business: none</p> <p>10.Concrete purpose/objective: For the capex of Guanyin Plant</p> <p>11.Any other matters that need to be specified: none</p>

2022/02/21	15:20:43	<p>Announcement of the high liquidity assets, short-term debt, short-term notes payable and long-term liabilities due within 1 year.</p> <ol style="list-style-type: none"> 1.Date of occurrence of the event:2022/02/21 2.Cause of occurrence: According to the letter No. 1091806531 of TWSE 3.Financial information date: January 2022 4.Cash and cash equivalents (Unit: NT'000):178,141 5.Financial assets at fair value through profit or loss–current (Unit: NT'000):293,891 6.Financial assets at fair value through other comprehensive income–current (Unit: NT'000):0 7.Non-current assets that are TWSE or GTSM listed securities (including unrealized valuation amount) (Unit: NT'000):0 8.Short-term debt (Unit: NT'000):0 9.Short-term notes payable (Unit: NT'000):0 10.Long-term liabilities due within 1 year (Unit: NT'000):0 11.Other accounting accounts (Unit: NT'000):0 12.Countermeasures: None. 13.Any other matters that need to be specified: None.
2022/03/18	15:18:02	<p>Board of Directors approved the consolidated financial statements.</p> <ol style="list-style-type: none"> 1.Date of submission to the board of directors or approval by the board of directors:2022/03/18 2.Date of approval by the audit committee:2022/03/18 3.Start and end dates of financial reports or annual self-assessed financial information of the reporting period (XXXX/XX/XX~XXXX/XX/XX): 2021/01/01~2021/12/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):64,217 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):208,089 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):73,658 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):65,506 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):55,696 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):55,696 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):0.58 11.Total assets end of the period (thousand NTD):4,189,895 12.Total liabilities end of the period (thousand NTD):869,264

		<p>13. Equity attributable to owners of parent end of the period (thousand NTD): 3,320,631</p> <p>14. Any other matters that need to be specified: NA</p>
2022/03/18	15:23:04	<p>The Board proposed no earnings distribution.</p> <p>1. Date of the board of directors resolution : 2022/03/18</p> <p>2. Year or quarter which dividends belong to: 2021</p> <p>3. Period which dividends belong to: 2021/01/01~2021/12/31</p> <p>4. Appropriations of earnings in cash dividends to shareholders (NT\$ per share): 0</p> <p>5. Cash distributed from legal reserve and capital surplus to shareholders (NT\$ per share): 0</p> <p>6. Total amount of cash distributed to shareholders (NT\$): 0</p> <p>7. Appropriations of earnings in stock dividends to shareholders (NT\$ per share): 0</p> <p>8. Stock distributed from legal reserve and capital surplus to shareholders (NT\$ per share): 0</p> <p>9. Total amount of stock distributed to shareholders (shares): 0</p> <p>10. Any other matters that need to be specified: 0</p> <p>11. Per value of common stock: 10</p>
2022/03/18	15:41:04	<p>Convention of 2022 general shareholders' meeting</p> <p>1. Date of the board of directors' resolution: 2022/03/18</p> <p>2. Shareholders meeting date: 2022/06/21</p> <p>3. Shareholders meeting location: NO.61, LN.309, HAIHU N. RD., LUZHU DIST. TAOYUAN CITY</p> <p>4. Shareholders meeting will be held by means of (physical shareholders meeting/ visual communication assisted shareholders meeting / visual communication shareholders meeting): physical shareholders meeting</p> <p>5. Cause for convening the meeting (1) Reported matters:</p> <p>(1) Report on the compensation for employees and directors of 2021</p> <p>(2) Report on the compensation for directors</p> <p>(3) Report on operating results of 2021</p> <p>(4) Report by Audit Committee on auditing of 2021 financial statements</p> <p>(5) Report on donation to related parties</p> <p>(6) Admissions to Sustainable Development Best Practice Principles</p> <p>6. Cause for convening the meeting (2) Acknowledged matters:</p> <p>(1) Recognition of 2021 operation report and financial statements</p> <p>(2) Distribution of retained earnings</p> <p>7. Cause for convening the meeting (3) Matters for Discussion:</p> <p>(1) Amendment to Article of Incorporation</p> <p>(2) Amendments to Procedure for Acquisition and Disposal of Assets</p> <p>(3) Amendment to Subsidiary's Procedure for Acquisition and Disposal of Assets</p> <p>(4) Lifting ban on directors from running the same business as SCI</p>

		<p>8.Cause for convening the meeting (4) Election matters: Election of directors.</p> <p>9.Cause for convening the meeting (5) Other Proposals: NA</p> <p>10.Cause for convening the meeting (6) Extemporary Motions: NA</p> <p>11.Book closure starting date:2022/04/23</p> <p>12.Book closure ending date:2022/06/21</p> <p>13.Any other matters that need to be specified: NA</p>
2022/05/06	16:26:55	<p>Board of Directors approved the consolidated financial statements.</p> <p>1.Date of submission to the board of directors or approval by the board of directors:2022/05/06</p> <p>2.Date of approval by the audit committee:2022/05/06</p> <p>3.Start and end dates of financial reports or annual self-assessed financial information of the reporting period (XXXX/XX/XX~XXXX/XX/XX): 2022/01/01~2022/03/31</p> <p>4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD): 188,023</p> <p>5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):55,162</p> <p>6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):18,226</p> <p>7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):52,006</p> <p>8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):41,173</p> <p>9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):41,173</p> <p>10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):0.43</p> <p>11.Total assets end of the period (thousand NTD):4,399,833</p> <p>12.Total liabilities end of the period (thousand NTD):1,020,180</p> <p>13.Equity attributable to owners of parent end of the period (thousand NTD):3,379,653</p> <p>14.Any other matters that need to be specified: NA</p>
2022/05/06	17:46:48	<p>Convention of 2022 general shareholders' meeting (Add one Matters for Discussion)</p> <p>1.Date of the board of directors' resolution:2022/05/06</p> <p>2.Shareholders meeting date:2022/06/21</p> <p>3.Shareholders meeting location: NO.61, LN.309, HAIHU N. RD., LUZHU DIST. TAOYUAN CITY</p> <p>4.Shareholders meeting will be held by means of (physical shareholders meeting/ visual communication assisted shareholders meeting / visual communication shareholders meeting): physical shareholders meeting</p> <p>5.Cause for convening the meeting (1) Reported matters:</p>

		<p>(1) Report on the compensation for employees and directors of 2021</p> <p>(2) Report on the compensation for directors</p> <p>(3) Report on operating results of 2021</p> <p>(4) Report by Audit Committee on auditing of 2021 financial statements</p> <p>(5) Report on donation to related parties</p> <p>(6) Amendments to Sustainable Development Best Practice Principles</p> <p>6.Cause for convening the meeting (2) Acknowledged matters:</p> <p>(1) Recognition of 2021 operation report and financial statements</p> <p>(2) Distribution of retained earnings</p> <p>7.Cause for convening the meeting (3) Matters for Discussion:</p> <p>(1) Amendment to Article of Incorporation</p> <p>(2) Amendment to Procedure for Acquisition and Disposal of Assets</p> <p>(3) Amendment to Subsidiary’s Procedure for Acquisition and Disposal of Assets</p> <p>(4) Lifting ban on directors from running the same business as SCI</p> <p>(5) Amendment to Rules of Procedure for Shareholders Meetings (Add)</p> <p>8.Cause for convening the meeting (4) Election matters: Election of directors.</p> <p>9.Cause for convening the meeting (5) Other Proposals: NA</p> <p>10.Cause for convening the meeting (6) Extemporary Motions: NA</p> <p>11.Book closure starting date:2022/04/23</p> <p>12.Book closure ending date:2022/06/21</p> <p>13.Any other matters that need to be specified: NA</p>
2022/06/21	15:08:13	<p>Notice of the resolutions of 2022 general shareholders' meeting.</p> <p>1.Date of the shareholders meeting:2022/06/21</p> <p>2.Important resolutions (1)Profit distribution/ deficit compensation:</p> <p>Approved the distribution of retained earnings.</p> <p>59,482,176 shares represented by shareholders present in person or by proxy. (including 13,345,863 shares casted electronically)</p> <p>approval votes : 57,958,135 votes – 97.43% of the total represented at the time of voting.</p> <p>disapproval votes : 163,350 votes – 0.27% of the total represented at the time of voting.</p> <p>invalid votes: 0 votes - 0% of the total represented at the time of voting.</p> <p>abstention votes/no votes : 1,360,691 votes – 2.28% of the total represented at the time of voting.</p> <p>3.Important resolutions (2)Amendments to the corporate charter:</p> <p>Approved the amendments to Article of Incorporation.</p> <p>59,482,176 shares represented by shareholders present in person or by proxy. (including 13,345,863 shares casted electronically)</p> <p>approval votes : 57,973,367 votes – 97.46% of the total represented at the time of voting.</p>

disapproval votes : 143,009 votes – 0.24% of the total represented at the time of voting.
invalid votes: 0 votes - 0% of the total represented at the time of voting.
abstention votes/no votes : 1,365,800 votes - 2.29% of the total represented at the time of voting.

4.Important resolutions (3)Business report and financial statements:

Approved the operation report and financial statements of 2021.
59,482,176 shares represented by shareholders present in person or by proxy.
(including 13,345,863 shares casted electronically)
approval votes : 59,019,579 votes – 99.22% of the total represented at the time of voting.
disapproval votes : 155,947 votes – 0.26% of the total represented at the time of voting.
invalid votes: 0 votes - 0% of the total represented at the time of voting.
abstention votes/no votes : 306,650 votes – 0.51% of the total represented at the time of voting.

5.Important resolutions (4)Elections for board of directors and supervisors:

Re-election of directors.

Elected as below:

Directors:

(1)Mr. Weichyun Wong; 70,170,503 votes

(2)Mr. Henry Chen; 59,035,593 votes

(3)Mercuries & Associates, Holding Ltd.

Representative: Ms. Aurora Chen; 59,028,179 votes

(4)Mercuries & Associates, Holding Ltd.

Representative: Mr. Wen-Chih Chou; 58,033,361 votes

Independent directors:

Mr. Ted Tu; 56,039,460 votes

Mr. Chia-Chun Jay Chen; 55,869,167 votes

Mr. Vincent Wang; 54,677,064 votes

6.Important resolutions (5)Any other proposals:

(1)Approved the amendments to Procedure for Acquisition and Disposal of Assets.

59,482,176 shares represented by shareholders present in person or by proxy.
(including 13,345,863 shares casted electronically)

approval votes : 59,031,261 votes – 99.24% of the total represented at the time of voting.

disapproval votes : 143,012 votes – 0.24% of the total represented at the time of voting.

invalid votes: 0 votes - 0% of the total represented at the time of voting.

abstention votes/no votes : 307,903 votes – 0.51% of the total represented

		<p>at the time of voting</p> <p>(2)Approved the amendments to Subsidiary’s Procedure for Acquisition and Disposal of Assets.</p> <p>59,482,176 shares represented by shareholders present in person or by proxy. (including 13,345,863 shares casted electronically)</p> <p>approval votes : 59,031,109 votes – 99.24% of the total represented at the time of voting.</p> <p>disapproval votes : 145,364 votes – 0.24% of the total represented at the time of voting.</p> <p>invalid votes: 0 votes - 0% of the total represented at the time of voting.</p> <p>abstention votes/no votes : 305,703 votes – 0.51% of the total represented at the time of voting.</p> <p>(3)Approved the amendments to Rules of Procedure for Shareholders Meetings.</p> <p>59,482,176 shares represented by shareholders present in person or by proxy. (including 13,345,863 shares casted electronically)</p> <p>approval votes : 59,030,968 votes – 99.24% of the total represented at the time of voting.</p> <p>disapproval votes : 144,214 votes – 0.24% of the total represented at the time of voting.</p> <p>invalid votes: 0 votes - 0% of the total represented at the time of voting.</p> <p>abstention votes/no votes : 306,994 votes – 0.51% of the total represented at the time of voting</p> <p>(4)Approved the lifting of ban on directors from running the same business as SCI.</p> <p>59,482,176 shares represented by shareholders present in person or by proxy. (including 13,345,863 shares casted electronically)</p> <p>approval votes : 59,001,500 votes – 99.19% of the total represented at the time of voting.</p> <p>disapproval votes : 165,997 votes – 0.27% of the total represented at the time of voting.</p> <p>invalid votes: 0 votes - 0% of the total represented at the time of voting.</p> <p>abstention votes/no votes : 314,679 votes – 0.52% of the total represented at the time of voting.</p> <p>7.Any other matters that need to be specified: NA</p>
2022/06/21	15:08:39	<p>List of the Company's elected directors.</p> <p>1.Date of occurrence of the change:2022/06/21</p> <p>2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor):</p> <p>juristic-person director, independent director, natural-person director</p> <p>3.Title and name of the previous position holder:</p>

		<p>(1)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Weichyun Wong</p> <p>(2)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Henry Chen</p> <p>(3)Director: Mercuries & Associates, Holding Ltd. Representative : Ms. Aurora Chen</p> <p>(4)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Wen-Chih Chou</p> <p>(5)Independent director: Mr. Ted Tu</p> <p>(6)Independent director: Mr. Hung-Chih Wu</p> <p>(7)Independent director: Mr. Chia-Chun Jay Chen</p> <p>4.Resume of the previous position holder:</p> <p>(1)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Weichyun Wong General manager of SCI Pharmtech, Inc.</p> <p>(2)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Henry Chen Chairman of Mercuries & Associates, Ltd.</p> <p>(3)Director: Mercuries & Associates, Holding Ltd. Representative : Ms. Aurora Chen Director of Shanghai American School</p> <p>(4)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Wen-Chih Chou R&D manager of SCI Pharmtech, Inc.</p> <p>(5)Independent director: Mr. Ted Tu Chairman of Hsuan Ho technology Ltd.</p> <p>(6)Independent director: Mr. Hung-Chih Wu General manager of CHENG FONG CHEMICAL CO., LTD.</p> <p>(7)Independent director: Mr. Chia-Chun Jay Chen Professor of Department of Chemistry, National Taiwan Normal University.</p> <p>5.Title and name of the new position holder:</p> <p>(1)Director: Mr. Weichyun Wong</p> <p>(2)Director: Mr. Henry Chen</p> <p>(3)Director: Mercuries & Associates, Holding Ltd. Representative : Ms. Aurora Chen</p> <p>(4)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Wen-Chih Chou</p> <p>(5)Independent director: Mr. Ted Tu</p> <p>(6)Independent director: Mr. Chia-Chun Jay Chen</p> <p>(7)Independent director: Mr. Vincent Wang</p> <p>6.Resume of the new position holder:</p>
--	--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

		<p>(1)Director: Mr. Weichyun Wong General manager of SCI Pharmtech, Inc.</p> <p>(2)Director: Mr. Henry Chen Chairman of Mercuries & Associates, Ltd.</p> <p>(3)Director: Mercuries & Associates, Holding Ltd. Representative : Ms. Aurora Chen Director of Yushan Pharmaceuticals Inc.</p> <p>(4)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Wen-Chih Chou Factory manager of SCI Pharmtech, Inc.</p> <p>(5)Independent director: Mr. Ted Tu Chairman of PharmaEngine, Inc.</p> <p>(6)Independent director: Mr. Chia-Chun Jay Chen Professor of Department of Chemistry, National Taiwan Normal University.</p> <p>(7)Independent director: Mr. Vincent Wang Chairman of SUNSINO DEVELOPMENT ASSOCIATE INC.</p> <p>7.Circumstances of change (Please enter “resignation”, “dismissal”, “term expired”, “death” or “new appointment”):tenure expired</p> <p>8.Reason for the change: re-election due to tenure expiration</p> <p>9.Number of shares held by the new position holder when elected:</p> <p>(1)Director: Mr. Weichyun Wong; 526,970 shares</p> <p>(2)Director: Mr. Henry Chen; 0 shares</p> <p>(3)Director: Mercuries & Associates, Holding Ltd. Representative : Ms. Aurora Chen; 30,283,358 shares</p> <p>(4)Director: Mercuries & Associates, Holding Ltd. Representative : Mr. Wen-Chih Chou; 30,283,358 shares</p> <p>(5)Independent director: Mr. Ted Tu; 0 share</p> <p>(6)Independent director: Mr. Chia-Chun Jay Chen; 0 share</p> <p>(7)Independent director: Mr. Vincent Wang; 6,000 shares</p> <p>10.Original term (from _____ to _____):2019/06/21~2022/06/20</p> <p>11.Effective date of the new appointment:2022/06/21</p> <p>12.Turnover rate of directors of the same term: NA</p> <p>13.Turnover rate of independent directors of the same term: NA</p> <p>14.Turnover rate of supervisors of the same term: NA</p> <p>15.Change in one-third or more of directors (Please enter “Yes” or “No”): No</p> <p>16.Any other matters that need to be specified: NA</p>
2022/06/21	15:09:10	<p>Notice of Lifting of ban on new directors from running the same business as SCI.</p> <p>1.Date of the shareholders meeting resolution:2022/06/21</p> <p>2.Name and title of the director with permission to engage in competitive conduct:</p> <p>(1)Director: Mr. Ted Tu, Chairman of PharmaEngine, Inc.</p>

		<p>(2)Director: Mr. Vincent Wang, Director of SUNDER BIOMEDICAL TECH. CO., LTD.</p> <p>3.Items of competitive conduct in which the director is permitted to engage: Companies running the same or similar businesses with SCI.</p> <p>4.Period of permission to engage in the competitive conduct: During the term of the Director.</p> <p>5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act): Approved by more than two thirds of the voting rights exercised by the shareholders representing a majority of the outstanding shares.</p> <p>6.If the permitted competitive conduct belongs to the operator of a mainland China area enterprise, the name and title of the directors (if it is not the operator of a Mainland-area enterprise, please enter “N/A” below):NA</p> <p>7.Company name of the mainland China area enterprise and the director's position in the enterprise: NA</p> <p>8.Address of the mainland China area enterprise: NA</p> <p>9.Operations of the mainland China area enterprise: NA</p> <p>10.Impact on the company's finance and business: NA</p> <p>11.If the directors have invested in the mainland China area enterprise, the monetary amount of the investment and their shareholding ratio: NA</p> <p>12.Any other matters that need to be specified: NA</p>
2022/06/21	15:09:37	<p>Notice of re-election of functional committees' Members</p> <p>1.Date of occurrence of the change:2022/06/21</p> <p>2.Name of the functional committees: Audit Committee & Remuneration Committee.</p> <p>3.Name of the previous position holder: Audit Committee & Remuneration Committee- Mr. Ted Tu Mr. Hung-Chih Wu Mr. Chia-Chun Jay Chen</p> <p>4.Resume of the previous position holder: Audit Committee & Remuneration Committee- Mr. Ted Tu, Chairman of Hsuan Ho technology Ltd. Mr. Hung-Chih Wu, General manager of CHENG FONG CHEMICAL CO., LTD. Mr. Chia-Chun Jay Chen, Professor of Department of Chemistry, National Taiwan Normal University.</p> <p>5.Name of the new position holder: Audit Committee & Remuneration Committee- Mr. Ted Tu Mr. Chia-Chun Jay Chen</p>

		<p>Mr. Vincent Wang</p> <p>6.Resume of the new position holder: Audit Committee & Remuneration Committee- Mr. Ted Tu, Chairman of PharmaEngine, Inc. Mr. Chia-Chun Jay Chen, Professor of Department of Chemistry, National Taiwan Normal University. Mr. Vincent Wang, Chairman of SUNSINO DEVELOPMENT ASSOCIATE INC.</p> <p>7.Circumstances of change (Please enter “resignation”, “dismissal”, “term expired”, “death” or “new appointment”):tenure expired</p> <p>8.Reason for the change: re-election due to tenure expiration</p> <p>9.Original term (from _____ to _____):2019/06/21~2022/06/20</p> <p>10.Effective date of the new member:2022/06/21</p> <p>11.Any other matters that need to be specified: NA</p>
2022/06/29	15:14:35	<p>Notice of the re-election of chairman of the Board of Directors.</p> <p>1.Date of the board of directors resolution or date of occurrence of the change:2022/06/29</p> <p>2.Position (Please enter chairperson or president/general manager): chairman</p> <p>3.Name of the previous position holder: Mr. Weichyun Wong</p> <p>4.Resume of the previous position holder: Chairman of SCI Pharmtech, Inc.</p> <p>5.Name of the new position holder: Mr. Weichyun Wong</p> <p>6.Resume of the new position holder: Chairman of SCI Pharmtech, Inc.</p> <p>7.Circumstances of change (Please enter ”resignation”, ”dismissal”, ”term expired”, ”job relocation”, ”severance”, ”retirement”, ”death” or ”new appointment”):term expired</p> <p>8.Reason for the change: re-election due to tenure expiration</p> <p>9.Effective date of the new appointment:2022/06/29</p> <p>10.Any other matters that need to be specified: NA</p>
2022/06/29	15:16:59	<p>Notice of appointment of general manager of the Board of Directors.</p> <p>1.Date of the board of directors resolution or date of occurrence of the change: 2022/06/29</p> <p>2.Position (Please enter chairperson or president/general manager): general manager</p> <p>3.Name of the previous position holder: Mr. Weichyun Wong</p> <p>4.Resume of the previous position holder: general manager of SCI Pharmtech, Inc.</p> <p>5.Name of the new position holder: Mr. Wen-Chih Chou</p> <p>6.Resume of the new position holder: Plant Manager of SCI Pharmtech, Inc.</p> <p>7.Circumstances of change (Please enter ”resignation”, ”dismissal”, ”term expired”, ”job relocation”, ”severance”, ”retirement”,</p>

		<p>”death” or ”new appointment”):Job relocation</p> <p>8.Reason for the change: Corporate governance</p> <p>9.Effective date of the new appointment:2022/06/29</p> <p>10.Any other matters that need to be specified: NA</p>
2022/06/29	15:17:24	<p>Donation to related party.</p> <p>1.Date of occurrence of the event:2022/06/29</p> <p>2.Reason for the donation: Support Criminal study</p> <p>3.Total amount of the donation:NTD600,000</p> <p>4.Counterparty to the donation: Criminal Investigation Foundation of R.O.C.</p> <p>5.Relationship with the Company: Related Party</p> <p>6.Name and resume of independent director(s) that expressed an objection or qualified opinion: NA</p> <p>7.Objection or qualified opinion by the aforementioned independent director(s):NA</p> <p>8.Any other matters that need to be specified: NA</p>
2022/08/10	15:42:53	<p>Board of Directors approved the consolidated financial statements.</p> <p>1.Date of submission to the board of directors or approval by the board of directors:2022/08/10</p> <p>2.Date of approval by the audit committee:2022/08/10</p> <p>3.Start and end dates of financial reports or annual self-assessed financial information of the reporting period (XXXX/XX/XX~XXXX/XX/XX): 2022/01/01~2022/06/30</p> <p>4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD): 369,384</p> <p>5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):115,235</p> <p>6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):33,602</p> <p>7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):228,020</p> <p>8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):181,515</p> <p>9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):181,515</p> <p>10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):1.90</p> <p>11.Total assets end of the period (thousand NTD):4,567,013</p> <p>12.Total liabilities end of the period (thousand NTD):1,055,060</p> <p>13.Equity attributable to owners of parent end of the period (thousand NTD):3,511,953</p> <p>14.Any other matters that need to be specified: NA</p>

2022/08/10	15:44:25	<p>To acquire right-of-use asset.</p> <p>1.Name and nature of the underlying asset (e.g., land located at Sublot XX, Lot XX, North District, Taichung City): Land located at 188-6, 3th Subsection, Industrial Park, Guanyin Dist., Taoyuan City</p> <p>2.Date of occurrence of the event:2022/08/10</p> <p>3.Transaction unit amount (e.g.XX square meters, equivalent to XX ping), unit price, and total transaction price: 4,230 square meters, 1,279.57ping Rental cost: 200,000/per month, including VAT. Right-of-use asset cost: 77,367 thousand</p> <p>4.Trading counterparty and its relationship with the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the trading counterparty is not required to be disclosed): Trading counterparty : Yushan Pharmaceuticals Inc. Its relationship with the Company : Subsidiary</p> <p>5.Where the trading counterparty is a related party, announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary amount of transfer: The reason for choosing the related party as trading counterparty: Business needs The previous owner: NA</p> <p>6.Where an owner of the underlying assets within the past five years has been a related party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship with the Company at the time of the transaction: NA</p> <p>7.Projected gain (or loss) through disposal (not applicable for acquisition of assets; those with deferral should provide a table explaining recognition):NA</p> <p>8.Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important terms and conditions: Terms of payment: 5-year lease term with rental to be paid monthly. Restrictive covenants in the contract, and other important terms and conditions: (1)The lease term shall be automatically extended for a period of five years unless agreed otherwise in writing. (2)During the lease term, landlord shall not sell or offer to sell any part of the leased land to a third party without first offering to sell such land to tenant in the same terms and conditions. (right of first refusal)</p> <p>9.The manner of deciding on this transaction (such as invitation to tender, price comparison, or price negotiation), the reference basis for the</p>
------------	----------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

		<p>decision on price, and the decision-making unit: The reference basis for the decision on price: Market price The decision-making unit: The Board of Directors</p> <p>10.Name of the professional appraisal firm or company and its appraisal price: NA 11.Name of the professional appraiser: NA 12.Practice certificate number of the professional appraiser: NA 13.The appraisal report has a limited price, specific price, or special price: NA 14.An appraisal report has not yet been obtained: NA 15.Reason for an appraisal report not being obtained: NA 16.Reason for any significant discrepancy with the appraisal reports and opinion of the CPA:NA 17.Name of the CPA firm: NA 18.Name of the CPA:NA 19.Practice certificate number of the CPA:NA 20.Broker and broker's fee: NA 21.Concrete purpose or use of the acquisition or disposal: Business needs 22.Any dissenting opinions of directors to the present transaction: NA 23.Whether the counterparty of the current transaction is a related party: Yes 24.Date of the board of directors resolution:2022/08/10 25.Date of ratification by supervisors or approval by the audit committee:2022/08/10 26.The transaction is to acquire a real property or right-of-use asset from a related party: Yes 27.The price assessed in accordance with the Article 16 of the Regulations Governing the Acquisition and Disposal of Assets by Public Companies: NA 28.Where the above assessed price is lower than the transaction price, the price assessed in accordance with the Article 17 of the same regulations: NA 29.Any other matters that need to be specified: NA</p>
2022/09/28	18:27:10	<p>To acquire the wastewater treatment equipment.</p> <p>1.Name and nature of the underlying asset (e.g., land located at Sublot XX, Lot XX, North District, Taichung City): Name of the asset: Wastewater Treatment Equipment Located at 188-6, 3th Subsection, Industrial Park, Guanyin Dist., Taoyuan City</p> <p>2.Date of occurrence of the event:2022/09/28</p> <p>3.Transaction unit amount (e.g. XX square meters, equivalent to XX ping), unit price, and total transaction price: The asset cost: NTD 247million</p> <p>4.Trading counterparty and its relationship with the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the trading counterparty is not required to be disclosed): Trading counterparty : Framosa Co., Ltd.</p>

		<p>Its relationship with the Company : Related party</p> <p>5.Where the trading counterparty is a related party, announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary amount of transfer:</p> <p>The reason for choosing the related party as trading counterparty: Framosa Co., Ltd has expertise authorized by Veolia Group.</p> <p>The previous owner: NA</p> <p>6.Where an owner of the underlying assets within the past five years has been a related party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship with the Company at the time of the transaction: NA</p> <p>7.Projected gain (or loss) through disposal (not applicable for acquisition of assets; those with deferral should provide a table explaining recognition):NA</p> <p>8.Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important terms and conditions: Payment according to the progress of the project, payment term 30 days. After the completion of the wastewater treatment equipment, the operation will be entrusted to Framosa Co., Ltd.</p> <p>9.The manner of deciding on this transaction (such as invitation to tender, price comparison, or price negotiation), the reference basis for the decision on price, and the decision-making unit: The reference basis for the decision on price: Price negotiation The decision-making unit: The Board of Directors</p> <p>10.Name of the professional appraisal firm or company and its appraisal price: NA</p> <p>11.Name of the professional appraiser: NA</p> <p>12.Practice certificate number of the professional appraiser: NA</p> <p>13.The appraisal report has a limited price, specific price, or special price: NA</p> <p>14.An appraisal report has not yet been obtained: NA</p> <p>15.Reason for an appraisal report not being obtained: NA</p> <p>16.Reason for any significant discrepancy with the appraisal reports and opinion of the CPA:NA</p> <p>17.Name of the CPA firm: NA</p> <p>18.Name of the CPA:NA</p> <p>19.Practice certificate number of the CPA:NA</p> <p>20.Broker and broker's fee: NA</p> <p>21.Concrete purpose or use of the acquisition or disposal: For complying with the environmental regulations, Guanyin Factory needs the wastewater treatment equipment to handle manufacturing process</p>
--	--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

		<p>wastewater.</p> <p>22.Any dissenting opinions of directors to the present transaction: NA</p> <p>23.Whether the counterparty of the current transaction is a related party: Yes</p> <p>24.Date of the board of directors resolution:2022/09/28</p> <p>25.Date of ratification by supervisors or approval by the audit committee:2022/09/28</p> <p>26.The transaction is to acquire a real property or right-of-use asset from a related party: No</p> <p>27.The price assessed in accordance with the Article 16 of the Regulations Governing the Acquisition and Disposal of Assets by Public Companies: NA</p> <p>28.Where the above assessed price is lower than the transaction price, The price assessed in accordance with the Article 17 of the same regulations: NA</p> <p>29.Any other matters that need to be specified: Framosa was entrusted with the design, building and operation of this facility.</p>
2022/11/10	15:44:10	<p>Board of Directors approved the consolidated financial statements.</p> <p>1.Date of submission to the board of directors or approval by the board of directors:2022/11/10</p> <p>2.Date of approval by the audit committee:2022/11/10</p> <p>3.Start and end dates of financial reports or annual self-assessed financial information of the reporting period (XXXX/XX/XX~XXXX/XX/XX): 2022/01/01~2022/09/30</p> <p>4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD): 673,973</p> <p>5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):208,282</p> <p>6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD): 80,742</p> <p>7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD): 290,322</p> <p>8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):230,131</p> <p>9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):230,131</p> <p>10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):2.41</p> <p>11.Total assets end of the period (thousand NTD):4,618,383</p> <p>12.Total liabilities end of the period (thousand NTD):1,060,263</p> <p>13.Equity attributable to owners of parent end of the period (thousand NTD):3,558,120</p> <p>14.Any other matters that need to be specified: NA</p>
2022/11/10	16:26:14	Invited to brief recent operating results.

		<p>1.Date of institutional investor conference:2022/11/11</p> <p>2.Time of institutional investor conference:14:30</p> <p>3.Location of institutional investor conference:7F., No. 236, Sec. 4, Xinyi Rd., Taipei City</p> <p>4.Outline of institutional investor conference: Brief recent operating results</p> <p>5.Any other matters that need to be specified: NA</p>
2022/12/12	14:58:37	<p>Invited to brief recent operating results.</p> <p>1.Date of institutional investor conference:2022/12/13</p> <p>2.Time of institutional investor conference:15:20</p> <p>3.Location of institutional investor conference: 2F, Primasia Conference & Business Center</p> <p>4.Outline of institutional investor conference: Brief recent operating results</p> <p>5.Any other matters that need to be specified: NA</p>
2022/12/26	23:14:11	<p>Announcement that the board of directors approved the budget increase for Guanyin Factory.</p> <p>1.Date of occurrence of the event:2022/12/26</p> <p>2.Date of the original announcement and reporting:2021/09/15</p> <p>3.Summary of the content originally announced and reported: The original budget was 1.175 billion</p> <p>4.Reasons for the change and its main content: Due to inflation, an additional 598 million would be added.</p> <p>5.Effect on the Company's finance and business after the change: Bank loan will increase by 598 million accordingly.</p> <p>6.Any other matters that need to be specified: (1)The company announced the acquisition of waste treatment equipment of 247 million on Sep. 28, 2022. (2)The budget for Guanyin factory in total would be increased to 2.02 billion.</p>